|
US5418245A
|
|
Styryl-substituted monocyclic and bicyclic heteroaryl compounds which inhibit EGF receptor tyrosine kinase
|
|
AU669484B2
|
|
Transgenic protein production
|
|
WO9300357A1
|
|
Therapeutic polypeptides based on von willebrand factor
|
|
WO9220350A1
|
|
Aromatic oligomeric compounds useful as mimics of bioactive macromolecules
|
|
SG64322A1
|
|
Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
|
|
EP0577775A1
|
|
Anti-thrombotic peptides and pseudopeptides.
|
|
AU1642992A
|
|
Preparation of factor IX
|
|
AU2023292A
|
|
Enantioselective preparation of acetylenic or olefinic substituted cycloalkenyl dihydroxybutyrates and 4-hydroxy-tetrahydropyran-2-ones
|
|
WO9209284A1
|
|
2,6-methano-2h-1-benzoxocincarboxamides as 5-ht3-antagonists
|
|
IL99762A
|
|
Alpha-cyano-styryl-substituted pyridyl compounds which inhibit egf receptor tyrosine kinase and pharmaceutical compositions containing them
|
|
AU8726691A
|
|
Compounds having antihypertensive and anti-ischemic properties
|
|
WO9209592A1
|
|
Process for preparing multicyclic oxy-containing ring components
|
|
WO9204321A1
|
|
Substituted bicyclic aryl compounds exhibiting selective leukotriene b4 antagonist activity
|
|
AU8427391A
|
|
Fibroblast growth factor receptors
|
|
AU7756891A
|
|
Heterocyclicethenediyl compounds which inhibit EGF receptor tyrosine kinase
|
|
AU7797991A
|
|
Styryl-substituted indole and pyridyl compounds
|
|
CA2107893A1
|
|
Anti-thrombotic peptide and pseudopeptide derivatives
|
|
AU8089691A
|
|
Anti-thrombotic peptide and pseudopeptide derivatives
|
|
EP0510066A1
|
|
1-azetidyl and 1-hexamethylenimine alkyl or aryl bisphosphonic acids and their use as pharmacological agents
|
|
AU6919191A
|
|
Polymers with alkyl- or heteroalkyl-aryl backbone and pharmaceutical compositions incorporating same
|
